Issue 90

public listing

A public listing in psychedelic healthcare

Britain’s burgeoning psychedelic healthcare ecosystem includes leading research institutions, drug developers and clinical operations, with ancillary organisations providing essential financial and regulatory support.

Hill Dickinson provides legal advice to companies contributing to the future of psychedelic medicine on the continent. This includes protecting intellectual property, navigating regulatory processes and raising capital through public listing and private investment rounds.

The law firm has worked with several NHS bodies and over 100 healthcare clients, guiding Psych Capital through its public listing on the AQSE market – making it one of the first psychedelic healthcare companies to complete a public listing in London.

READ MORE

SEROTONIN HYPOTHESIS OF DEPRESSION DEBASED

A review found serotonin imbalances may not be the origin of depression, calling into question the use of SSRIs.

Read More

THE COMMERCIAL POTENTIAL OF PSYCHEDELIC MEDICINE

Psych Capital’s Co-founder, William Potts, spoke with The Investors Chronicle by Financial Times.

Read More

BUSINESS AND INVESTMENT

Numinus reports Q3 2022 results.

Kabir Nath takes over as COMPASS Pathways’ CEO.

George Tziras to become CEO of Small Pharma.

Remedy Institute MDMA study stopped over safety concerns.

Mydecine files patent on MDMA analogues.

Lobe Sciences files psilocin patent.

Accessibility is key to the success of psychedelic healthcare.

Hallucinations in psychedelic medicine.

Halucenex expands PTSD study to include patients on SSRIs.

Psychedelic medicines and mental health.

The Psychedelics as Medicine Report provides market intelligence from industry experts and thought leaders.

Previous sponsors include atai Life Sciences, COMPASS Pathways and Cybin.

Contact Grace@psych.global for partnership opportunities.

CONTACT FORM

SCIENCE AND RESEARCH

Study shows efficacy of ketamine therapy at-home.

The sentiment of investors in psychedelic medicine.

Ketamine for neonatal and paediatric epilepsy.

REGULATION AND LEGISLATION

A guide to Oregon’s psilocybin framework.

US House increases veteran access to psychedelic healthcare.

Royal College of Psychiatrists asked to support psilocybin rescheduling.

University of Utrecht studies MDMA regulation.

Australia’s first fixed drug-testing site opens.

Partner with us